Azenta Inc

Healthcare US AZTA

33.17USD
1.74(5.54%)

Last update at 2025-07-08T16:50:00Z

Day Range

31.4133.60
LowHigh

52 Week Range

38.8269.16
LowHigh

Fundamentals

  • Previous Close 31.43
  • Market Cap2135.12M
  • Volume216242
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA20.27M
  • Revenue TTM656.32M
  • Revenue Per Share TTM12.34
  • Gross Profit TTM 272.80M
  • Diluted EPS TTM-3.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -30.43300M -9.93600M -48.96900M 74.97M 9.94M
Minority interest - - - 0.00000M 0.00000M
Net income -14.25700M -11.28600M -28.86900M 64.85M 9.89M
Selling general administrative 316.28M 252.06M 252.10M 241.14M 211.96M
Selling and marketing expenses - - - - -
Gross profit 263.14M 255.58M 243.81M 380.02M 316.76M
Reconciled depreciation 85.58M 53.70M 65.33M 65.50M 54.45M
Ebit -44.40500M -4.00300M -46.54700M 78.46M 46.53M
Ebitda 41.18M 49.70M 18.79M 144.78M 102.88M
Depreciation and amortization 85.58M 53.70M 65.33M 66.32M 56.34M
Non operating income net other - 19.39M - - -
Operating income -73.12600M -4.00300M -46.54700M 78.46M 46.53M
Other operating expenses 752.17M 579.52M 544.41M 817.45M 733.44M
Interest expense 0.00000M 4.59M 2.04M 2.94M 22.25M
Tax provision -17.55000M 1.35M -20.10000M 9.94M -0.11100M
Interest income 43.73M 20.29M 0.63M 0.85M 1.45M
Net interest income 43.73M 15.70M -1.40500M -2.09500M -20.80100M
Extraordinary items - - - - -
Non recurring - 0.71M - - -
Other items - - - - -
Income tax expense -17.55000M 1.35M -20.10000M 9.94M 0.05M
Total revenue 665.07M 555.50M 513.70M 897.27M 781.87M
Total operating expenses 350.24M 279.61M 274.51M 300.20M 268.33M
Cost of revenue 401.93M 299.91M 269.89M 517.25M 465.11M
Total other income expense net 12.93M -5.93300M -2.42200M -3.48600M -36.59500M
Discontinued operations - 2144.14M 139.62M 91.22M 498.54M
Net income from continuing ops -12.88300M -11.28600M -28.86900M 65.03M 9.55M
Net income applicable to common shares - 2132.86M 110.75M 64.85M 437.42M
Preferred stock and other adjustments - - - - -
Breakdown 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Type yearly yearly yearly yearly yearly
Date 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Total assets 2100.04M 2885.72M 3716.12M 1819.51M 1559.12M
Intangible assets 248.03M 294.30M 178.40M 186.53M 218.32M
Earning assets - - - - -
Other current assets 82.75M 98.75M 640.01M 369.58M 50.61M
Total liab 331.07M 351.22M 352.74M 494.18M 345.51M
Total stockholder equity 1768.97M 2534.50M 3363.39M 1325.33M 1213.61M
Deferred long term liab - - 64.56M - -
Other current liab 115.15M 140.52M 152.14M 128.94M 117.18M
Common stock 0.59M 0.71M 0.89M 0.88M 0.87M
Capital stock - 0.71M 0.89M 0.88M 0.87M
Retained earnings 1476.84M 1641.01M 1655.36M -470.05100M -551.07200M
Other liab - - 72.96M 54.34M 65.69M
Good will 691.41M 784.34M 513.62M 469.36M 501.54M
Other assets - - 58.26M 202.29M 129.15M
Cash 310.93M 678.91M 658.27M 227.43M 295.65M
Cash and equivalents - - - - -
Total current liabilities 204.84M 210.93M 230.55M 345.09M 211.12M
Current deferred revenue 31.98M 34.61M 39.75M 25.72M 31.36M
Net debt -252.13700M -618.47400M -609.04700M -132.66200M -213.37900M
Short term debt - - - 148.06M 0.83M
Short long term debt - - - - 0.83M
Short long term debt total 58.79M 60.44M 49.23M 94.77M 82.27M
Other stockholder equity 305.00M 955.20M 1791.06M 1775.16M 1741.89M
Property plant equipment - - 154.47M 180.37M 112.06M
Total current assets 832.81M 1418.96M 2459.35M 777.37M 649.45M
Long term investments - 111.34M 352.02M 3.60M 3.10M
Net tangible assets - - 2671.36M 669.44M 548.11M
Short term investments 151.16M 338.87M 911.76M 0.08M 0.07M
Net receivables 172.71M 156.53M 163.76M 119.88M 188.29M
Long term debt - - - 49.68M 49.59M
Inventory 115.26M 128.20M 85.54M 60.40M 114.83M
Accounts payable 44.43M 35.80M 38.65M 42.36M 61.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -13.46400M -62.42600M -83.91600M 19.35M 21.92M
Additional paid in capital - - - - -
Common stock total equity - - 0.89M - -
Preferred stock total equity - - - - -
Retained earnings total equity - - 1655.36M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 60.31M 70.47M 57.09M 241.90M 64.07M
Deferred long term asset charges - - - - -
Non current assets total 1267.23M 1466.76M 1256.78M 1042.15M 909.67M
Capital lease obligations - 60.44M 49.23M 45.09M 31.86M
Long term debt total - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments 431.38M -1270.21500M -0.03000M 33.93M 16.23M
Change to liabilities - 12.67M 27.03M 0.65M 8.91M
Total cashflows from investing activities - 1465.59M -146.34900M -22.74200M 211.31M
Net borrowings - -50.11300M -1.99200M -2.10500M -165.00100M
Total cash from financing activities -844.08000M -62.76200M -25.90600M -27.02300M -191.16100M
Change to operating activities - 13.22M 41.85M 18.57M 11.74M
Net income -14.25700M 2132.86M 110.75M 64.85M 437.75M
Change in cash -357.25100M 755.96M -17.19300M -2.64500M 107.46M
Begin period cash flow 1041.30M 285.33M 302.53M 305.17M 197.71M
End period cash flow 684.04M 1041.30M 285.33M 302.53M 305.17M
Total cash from operating activities 17.49M -466.04600M 149.86M 37.87M 90.90M
Issuance of capital stock 0.00000M 5.25M 5.81M 4.59M 3.42M
Depreciation 85.58M 53.70M 65.33M 65.50M 54.45M
Other cashflows from investing activities - 2809.24M 0.20M -1.00000M -1.00000M
Dividends paid 0.00000M 7.49M 29.73M 29.51M 28.89M
Change to inventory 5.77M -66.62900M -50.44300M -13.14400M -2.93300M
Change to account receivables 33.99M -31.39700M -69.64300M -18.75500M -12.50400M
Sale purchase of stock -838.51400M 5.25M 0.83M 0.83M 686.39M
Other cashflows from financing activities -4.98800M -10.40000M -0.82800M -0.82800M -0.68700M
Change to netincome - -2580.47400M 24.99M -79.81200M -407.24100M
Capital expenditures 39.44M 77.44M 52.80M 39.92M 23.86M
Change receivables - -31.39700M - - -
Cash flows other operating - -467.54000M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 936.78M - - -
Change in working capital -18.26500M -72.13300M -51.21100M -12.67100M 4.86M
Stock based compensation 9.38M 10.67M 27.46M 16.32M 20.11M
Other non cash items -16.71200M -2615.60900M 14.80M -90.72200M -411.11500M
Free cash flow -21.94600M -543.48100M 97.05M -2.05800M 67.04M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AZTA
Azenta Inc
1.74 5.54% 33.17 - 28.90 3.25 1.18 2.55 93.83
ISRG
Intuitive Surgical Inc
-6.47 1.21% 528.24 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
1.49 1.07% 140.33 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
9.13 3.37% 279.90 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
1.15 0.66% 174.10 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Azenta Inc

200 Summit Drive, Burlington, MA, United States, 01803

Key Executives

Name Title Year Born
Dr. Stephen S. Schwartz CEO, Pres & Director 1959
Mr. Lindon G. Robertson Exec. VP & CFO 1962
Mr. Robin Vacha Sr. VP of Global Operations 1976
Mr. Michael Paulo VP and Chief Information & Digital Officer NA
Sara Silverman Head of Investor Relations NA
Mr. Jason W. Joseph Sr. VP, Gen. Counsel & Corp. Sec. 1971
Mr. John E. O'Brien Sr. VP of Corp. Devel. 1970
Ms. Claribel Purcell Sr. VP of Global Sales NA
Ms. Kimberly Crowley Sr. VP & Chief HR Officer 1978
Mr. J. Robert Woodward Sr. VP of Global Quality & Regulatory NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.